228 related articles for article (PubMed ID: 28039713)
21. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors for prolonged survival in recurrent endometrial carcinoma: Implications for follow-up protocol.
Otsuka I; Uno M; Wakabayashi A; Kameda S; Udagawa H; Kubota T
Gynecol Oncol; 2010 Dec; 119(3):506-10. PubMed ID: 20837356
[TBL] [Abstract][Full Text] [Related]
23. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
24. Uterine endometrial carcinoma: 10 years' experience with long-term follow-up at a single Korean institution.
Lee EJ; Kim TJ; Choi CH; Lee JW; Lee JH; Bae DS; Park HM; Kim BG
Gynecol Obstet Invest; 2012; 74(4):313-9. PubMed ID: 23075517
[TBL] [Abstract][Full Text] [Related]
25. Expression of PTEN and β-Catenin and Their Relationship With Clinicopathological and Prognostic Factors in Endometrioid Type Endometrial Cancer.
Sal V; Demirkiran F; Erenel H; Tokgozoglu N; Kahramanoglu I; Bese T; Turan H; Sofiyeva N; Calay Z; Arvas M; Guralp O
Int J Gynecol Cancer; 2016 Mar; 26(3):512-20. PubMed ID: 26894937
[TBL] [Abstract][Full Text] [Related]
26. The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer.
Nakamura K; Hongo A; Kodama J; Hiramatsu Y
Gynecol Oncol; 2011 Oct; 123(1):82-7. PubMed ID: 21764107
[TBL] [Abstract][Full Text] [Related]
27. Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.
Nakamura K; Imafuku N; Nishida T; Niwa I; Joja I; Hongo A; Kodama J; Hiramatsu Y
Gynecol Oncol; 2012 Feb; 124(2):335-9. PubMed ID: 22008707
[TBL] [Abstract][Full Text] [Related]
28. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.
Yang B; Shan B; Xue X; Wang H; Shan W; Ning C; Zhou Q; Chen X; Luo X
PLoS One; 2016; 11(5):e0155145. PubMed ID: 27163153
[TBL] [Abstract][Full Text] [Related]
29. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients.
Yoon SO; Kim YT; Jung KC; Jeon YK; Kim BH; Kim CW
Lung Cancer; 2011 Feb; 71(2):209-16. PubMed ID: 20471712
[TBL] [Abstract][Full Text] [Related]
30. [The importance of HE4 in differential diagnosis of endometrial cancer].
Minář L; Klabenešová I; Jandáková E
Ceska Gynekol; 2015 Aug; 80(4):256-63. PubMed ID: 26265413
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma.
Saarelainen SK; Peltonen N; Lehtimäki T; Perheentupa A; Vuento MH; Mäenpää JU
Am J Obstet Gynecol; 2013 Aug; 209(2):142.e1-6. PubMed ID: 23583212
[TBL] [Abstract][Full Text] [Related]
32. Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC.
Sun R; Liu Z; Ma G; Lv W; Zhao X; Lei G; Xu C
Int J Clin Exp Pathol; 2015; 8(3):2392-9. PubMed ID: 26045746
[TBL] [Abstract][Full Text] [Related]
33. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.
Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK
Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study.
Athanassiadou P; Athanassiades P; Grapsa D; Gonidi M; Athanassiadou AM; Stamati PN; Patsouris E
Int J Gynecol Cancer; 2007; 17(3):697-704. PubMed ID: 17504383
[TBL] [Abstract][Full Text] [Related]
35. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
36. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
Pasanen A; Loukovaara M; Tuomi T; Bützow R
Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
[TBL] [Abstract][Full Text] [Related]
37. HE4 is an independent prognostic marker in endometrial cancer patients.
Mutz-Dehbalaie I; Egle D; Fessler S; Hubalek M; Fiegl H; Marth C; Widschwendter A
Gynecol Oncol; 2012 Aug; 126(2):186-91. PubMed ID: 22525819
[TBL] [Abstract][Full Text] [Related]
38. The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma.
Modarres-Gilani M; Vaezi M; Shariat M; Zamani N; Nourizadeh R
Cancer Biomark; 2017 Aug; 20(2):135-141. PubMed ID: 28800309
[TBL] [Abstract][Full Text] [Related]
39. Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.
Quan Q; Liao Q; Yin W; Zhou S; Gong S; Mu X
Sci Rep; 2021 Nov; 11(1):21694. PubMed ID: 34737393
[TBL] [Abstract][Full Text] [Related]
40. Tissue and serum CA125 expression in endometrial cancer.
Ginath S; Menczer J; Fintsi Y; Ben-Shem E; Glezerman M; Avinoach I
Int J Gynecol Cancer; 2002; 12(4):372-5. PubMed ID: 12144685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
